Epilepsy in Pregnant Women

Area of Science:

• Neurology
• Obstetrics
• Pharmacology

Background:

• Epilepsy affects women of childbearing potential, necessitating careful management during pregnancy.
• Unplanned pregnancies are common, highlighting the need for optimized anti-epileptic drug (AED) regimens.
• Conventional AEDs (US FDA class C or D) carry risks of major and minor anomalies.

Purpose of the Study:

• To provide guidance on managing epilepsy in women of childbearing potential.
• To emphasize the importance of pre-conception counseling and treatment optimization.
• To inform about AED teratogenicity, seizure risk during pregnancy, and labor complications.

Main Methods:

• Review of current literature and clinical guidelines for epilepsy management in pregnancy.
• Emphasis on individualized treatment strategies, including monotherapy and dose adjustments.
• Recommendations for prenatal counseling and risk communication.

Main Results:

• Monotherapy with the lowest effective AED dosage is recommended.
• AED withdrawal may be considered pre-conception; polytherapy increases risks.
• Valproic acid and carbamazepine carry specific risks for neural tube defects.
• Serum AED levels require monitoring throughout pregnancy, with adjustments based on clinical status.
• Vitamin K supplementation is recommended for mothers on enzyme-inducing AEDs and for newborns.

Conclusions:

• Optimizing AED treatment before conception is crucial for women with epilepsy.
• Continuous monitoring and individualized adjustments are necessary during pregnancy.
• Informed decision-making through prenatal counseling is vital for managing risks associated with AEDs and pregnancy.